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ABSTRACT: The proteasome, a validated anticancer target, participates
in an array of biochemical activities, which range from the proteolysis of
defective proteins to antigen presentation. We report the preparation of
biochemically and photophysically distinct green, red, and far-red real-
time sensors designed to simultaneously monitor the proteasome’s
chymotrypsin-, trypsin-, and caspase-like activities, respectively. These
sensors were employed to assess the effect of simultaneous multiple
active site catalysis on the kinetic properties of the individual subunits.
Furthermore, we have found that the catalytic signature of the
proteasome varies depending on the source, cell type, and disease
state. Trypsin-like activity is more pronounced in yeast than in mammals, whereas chymotrypsin-like activity is the only activity
detectable in B-cells (unlike other mammalian cells). Furthermore, chymotrypsin-like activity is more prominent in transformed
B cells relative to their counterparts from healthy donors.
The proteasome serves as the primary proteolytic enzymeregulating the removal of polyubiquitinated proteins,1,2
small monoubiquitinated proteins,3and peptides4 in eukaryotic
cells. Protein degradation is an essential participant in the
immune response,5 autophagy,6 cardiac hypertrophy,7 neuro-
degeneration,8 and cancer.9−11 The multisubunit proteasome
contains a 20S core particle that is responsible for ATP-
independent proteolysis of proteins. Associated regulator
particles such as the 19S cap mediate deubiquitination, ATP-
dependent substrate unfolding, and gate opening as well as
access to the catalytic chamber of the proteasome core
cylinder.1 The 20S core particle is an assembly of two outer
α-rings and 2 inner β-rings, each composed of 7 subunits. In the
constitutive proteasome, found in all cells, each inner β-ring
houses three distinct subunits that possess unique catalytic
activities: caspase-like (CaL; β1 subunit), trypsin-like (TL; β2
subunit), and chymotrypsin-like (ChL; β5 subunit).1 Each of
the latter subunits can be replaced by the immunoproteasome
subunits β1i, β2i, and β5i, resulting in either mixed proteasomes
with one or two subunits replaced or the full immunoprotea-
some when all three are substituted.12
It is beginning to emerge that total proteasome activity and
the ratios of the ChL, TL, and CaL activities, defined here as
the proteasome catalytic signature, may vary depending on
numerous factors. For example, proteasomes isolated from
different species have altered processivity of proteins due to
differences in catalytic rate of cleavage as well as turnover
rates.13 In addition, several laboratories have shown that
proteasome composition and activity vary in different tissue and
cell lines.14,15 Even within a cell type there appears to be an
assortment of factors that can alter proteasome activity such as
age,16 oxidative stress,17 and disease state.7−11 Furthermore, it
has been suggested that ChL proteasome activity is elevated in
cancer, although this proposal is controversial.18−20 Further-
more, the importance of the proteasome’s catalytic signature
extends beyond a possible correlation between activity and cell
type or disease state. For example, several antineoplastic agents
that target the proteasome do so by interfering with ChL
activity.20 However, recent studies suggest that therapeutic
efficacy may be enhanced by the presence of inhibitors that
block CaL and TL activities as well.21−24 In addition, clinical
resistance to the proteasome inhibitor bortezomib has been at
least partially ascribed to mutations in the ChL subunit.25,26
Consequently, methods that furnish subunit-specific measure-
ments of proteasome activity offer potential insight into the
mechanism of action and resistance to current drugs as well as
assistance in the identification of the appropriate drug cocktail.
The vast majority of kinetic studies carried out on the 20S
proteasome have utilized fluorophore-labeled peptides that are
biochemically acted upon by the individual active sites.
However, these proteasome substrates employ luciferin27 or
fluorophores with similar photophysical properties, all of which
are excited at wavelengths shorter than 400 nm.4,28−30 Activity-
based probes (ABPs), which target and covalently label the
enzyme active site with a fluorophore, have also been described
and used to assess the functional proteomics of the
proteasome.31−33 ABPs and fluorogenic substrates are comple-
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mentary methods that probe distinct elements of proteasome
function.33 There is considerable interest in identifying probes
that discriminate between and simultaneously assess the
catalytic subunits of the proteasome.34−36 In this regard, we
report the first example of a set of fluorescent real-time sensors
capable of simultaneously monitoring all three of the catalytic
activities of the proteasome and thereby furnish the catalytic
signature of this multimeric multifunctional enzyme complex.
We have found that catalytic activity in one subunit can be
influenced by simultaneous activity in the other active sites. In
addition, the catalytic signature varies in proteasomes isolated
from different cell types and disease states and thus potentially
serves as a fingerprint of the major source of proteolysis in cells.
■ RESULTS AND DISCUSSION
Design of Proteasome Sensors. Proteasome-specific
monitoring of CaL, ChL, and TL enzymatic activities presents
a number of molecular engineering challenges. First, the
simultaneous assessment of three separate enzyme-catalyzed
reactions requires the use of fluorophores with distinct
photophysical properties. Second, these fluorophores must be
embedded on substrates specific for the three individual
catalytic entities of the proteasome. Although selective
peptide-based substrates for CaL, ChL, and TL have been
described, the luminescent readouts4,37 for these sensors are
identical and therefore preclude the ability to simultaneous
measure the individual CaL, ChL, and TL protease activities. A
wide variety of photophysically distinct fluorescent labels are
available ranging in size from small well-defined fluorophores38
to large nanoparticles.39 Internally quenched peptides, species
that contain a fluorophore on one end of the peptide chain and
a fluorescent quencher on the other, have seen significant
application as protease sensors.39 Proteolysis liberates the
fluorophore from the quencher and thereby furnishes a
fluorescent readout. However, this approach poses additional
challenges with respect to the proteasome since it potentially
requires the identification of three distinct photophysically
robust fluorophore/quencher pairs (i.e., relief of a deep
fluorescent quench upon proteolysis). Furthermore, the
fluorophore and quencher substituents would need to be
readily accommodated within the proteasome’s narrow central
channel. We recently described a broad spectrum dark
fluorescent quencher, a derivative of acid blue 40 (AB40),
that can be used in conjunction with fluorophores that exhibit
excitation wavelengths from 340 to 680 nm.40 The broad
spectral footprint of AB40 (Supporting Information Figure 1),
along with its modest size, suggests that it might prove to be
useful in providing the desired fluorescent sensors for each
activity (Figure 1).
A small library of sensors was synthesized by appending
photochemically distinct fluorophores to the N-terminus of the
recognition sequences selective for each proteasomal activity
(ChL, HHSL; TL, LRR; CaL, nLPnLD).29 The fluorophore−
peptide−AB40 sensors include fluorescein (FAM where λex =
488 nm) for ChL, tetramethylrhodamine (TAMRA where λex =
550 nm) for TL, and DyLight633 (λex = 633) for CaL (Figure 2
and Supporting Information Figures 2−3). AB40 is appended
to the side chain of the C-terminal lysine residue on each
sensor.
Characterization of Proteasome Sensors. The kinetic
rates of proteolysis and maximum fold fluorescent increases for
the three sensors are listed in Table 1. ChL1−488 is rapidly
Figure 1. Multicolor monitoring of proteasome activity.
Figure 2. General structures of the proteasome sensors.
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hydrolyzed at all concentrations relative to that of its TL1−550
and CaL1−633 counterparts (Table 1). Efforts to improve the
proteolysis rates by synthesizing peptides with different linkers
between the peptide sequence and C-terminal Lys(AB40)
resulted in nonspecific cleavage by the proteasome (data not
shown). The Km values were not determined because the
sensors begin to aggregate at 10 μM, which is less than the
presumed Km.
4,29,30 Nonetheless, all sensors generate a robust
fluorescent increase (30−140-fold) upon proteolysis.
We assessed the active site selectivity of each sensor using
mutated proteasomes from yeast41 as well as a variety of
proteasome inhibitors with known active site preferences. All
three catalytic β-subunits are synthesized as preproteins that
require cleavage, exposing a critical N-terminal Thr residue
important for catalytic activity. Deleted preprotein sequences
are Nα-acetylated, resulting in partial proteasome inactiva-
tion.41,42 Four strains with such proteasome deletions were
analyzed: CaL mutant, ChL mutant, TL mutant, and CaL + TL
double deletion. We note that, although these deletions are
known to result in a complete loss of CaL activity, only a partial
loss in activity occurs with this mutation in the ChL and TL
active sites.41 In all instances, the rate of proteolysis of the
sensors appropriately reflects the complete/partial loss of
activity of the mutated proteasome catalytic sites (Supporting
Information Table 1). For example, the CaL1−633 sensor is
not proteolyzed by the proteasome containing the mutation in
the CaL subunit, but it is cleaved by proteasomes containing
the same mutations in either the ChL or TL subunit. A further
assessment of the selectivity of each sensor was accomplished
by using the proteasome inhibitors Ac-APnLD-aldehyde (CaL
inhibitor),29 epoxomicin (ChL inhibitor),43 MG132 (ChL and
CaL inhibitor),44 and TLCK (TL inhibitor).45 Each inhibitor
was preincubated with the proteasome in order to form either a
covalent or reversible adduct within the targeted active site. As
expected, the CaL-targeted Ac-APnLD-aldehyde (IC50 = 2.3 ±
0.6 μM) and MG132 (IC50 = 180 ± 150 μM) both inhibit
CaL1−633 proteolysis (Supporting Information Figures 5−8
and Table 2). Proteolysis of the ChL sensor, ChL1−488, is
inhibited by the ChL-targeted inhibitors epoxomicin (IC50 =
0.08 ± 0.03 μM) and MG132 (IC50 = 0.62 ± 0.06 μM). Finally,
hydrolysis of the TL sensor, TL1−550, is compromised by the
TL-directed inhibitor TLCK (IC50 = 210 ± 20 μM). In
summary, the ChL-, TL-, and CaL-targeted sensors selectively
detect, in the expected fashion, the loss of specific active site
activity due to mutation or added inhibitor with known active
site selectivity.
Simultaneous Monitoring of Proteasome Activities.
We optimized the conditions for simultaneously monitoring all
three proteasomal activities by first assessing the conditions for
two-site multicolor visualization (i.e., ChL + TL; CaL + TL;
CaL + ChL). This multistep process is critical since occupancy
at one active site can influence the catalytic activity at a second
active site.28,35 Indeed, the rate of proteolysis of ChL1−488 is
reduced by up to 50% in the presence of TL1−550 and up to
90% in the presence of CaL1−633 (Figure 3a,b). These
observations appear to be consistent with studies by Kisselev
and colleagues who found that inhibitors of CaL and TL sites
sensitize cells to inhibitors that target ChL sites.21,23 Perhaps
Table 1. Characterization of Activity-Selective Proteasome Sensors
specific activity (nmol min−1 mg−1 enzyme) fold change
proteasome sensor 2.5 μM 5 μM 2.5 μM 5 μM
FAM−HHSLK(AB40) ChL1−488 0.22 ± 0.02 0.31 ± 0.03 127 ± 2.6 137 ± 7.8
DyLight633−nLPnLDK(AB40) CaL1−633 0.03 ± 0.001 0.02 ± 0.002 32 ± 1.9 29 ± 0.2
TAMRA−LRRK(AB40) TL1−550 0.05 ± 0.003 0.06 ± 0.001 32 ± 2.9 31 ± 1.7
Figure 3. Optimization of the proteasome assay. Influence of each proteasome sensor on the activity of the other subunits. ChL1−488 activity with
(a) TL1−550 or (b) CaL1−633; TL1−550 activity with (c) ChL1−488 or (d) CaL1−633; CaL1−633 activity with (e) ChL1−488 or (f) TL1−550.
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not surprisingly, CaL activity is likewise suppressed in the
presence of the ChL substrate (Figure 3e). However, quite
unexpectedly, we found that the rate of TL1−550 hydrolysis is
actually enhanced (up to 5-fold) when ChL1−488 is present
(Figure 3c). Finally, TL activity is reduced in the presence of
CaL1−633, and CaL activity is impaired in the presence of
TL1−550 (Figure 3d,f). These results highlight the intricate
enzymological relationships of the individual proteolytic active
sites of the proteasome.
We subsequently evaluated the simultaneous three-color
monitoring of all proteasomal hydrolytic activities (Supporting
Information Figure 9) and identified optimized sensor
concentrations (0.5 μM ChL1−488, 1.0 μM TL1−550, and
1.0 μM CaL1−633; Supporting Information Figure 10). Under
these conditions, ChL1−488 is cleaved substantially faster than
that of TL1−550 and CaL1−633. However, the kinetic activity
for all three sensors is readily and reproducibly measured. We
once again utilized impaired proteasomes from yeast and a
variety of active site-selective inhibitors to verify that each
sensor monitors its designated proteasome activity. The sensors
detect the loss of activity in the yeast deletions in the expected
active site-selective fashion (Supporting Information Table 3).
Furthermore, incubation of wild-type proteasome with CaL-
targeted Ac-APnLD-aldehyde or MG132 (high concentrations)
impairs CaL1−633 cleavage, ChL-directed epoxomicin or
MG132 (low or high concentration) inhibits ChL1−488
proteolysis (Supporting Information Figure 11), and the
combination of CaL inhibitor Ac-APnLD-aldehyde and ChL-
inhibitor epoxomicin blocks both ChL and CaL activities.
Multicolor Proteasome Sensor Assay: Proteasome
Catalytic Signature. Confirmation that these sensors can
yield an assessment of the proteasome catalytic activities from
cell cultures was performed by using isolated proteasomes from
HeLa cells that are devoid of other proteases.4 This protocol
employs a cytosolic lysate that is generated upon incubation
with digitonin, followed by centrifugation, thereby separating
proteins associated with membranes (cell membrane fraction).
The cytosolic fraction is subjected to ultracentrifugation,
thereby pelleting the proteasome (cytosolic supernatant and
cytosolic pellet) (Supporting Information Figure 12). Testing
of the membrane and cytosolic supernatant fractions with
ChL1−488, TL1−550, and CaL1−633 indicated cleavage of all
sensors. The most likely explanation for this is the presence of
other proteases in these fractions because immunodepletion
with a 20S core particle antibody only slightly reduced the
activities (data not shown). However, greater than 95% of the
cytosolic pellet activity is exclusively due to the proteasome,
which can be removed by immunodepletion (Figure 4a).
Furthermore, we were able to reproducibly acquire TL/ChL,
CaL/ChL, and TL/CaL catalytic ratios from HeLa cells (Figure
4b). One major advantage of the single-well three-sensor assay
is that the ratios are independent of the amount of proteasome
present and therefore create consistent data that is easily
evaluated for comparison between separate samples.
Does the Proteasome Catalytic Signature Vary
among Different Species and Cell Types? The proteasome
is found in all eukaryotes and some prokaryotes. Not
surprisingly, significant structural and enzymological differences
exist between and within individual species. For example,
proteasomal processivity, the degree to which substrates are
degraded to small peptides, increases as a function of increasing
species complexity.13 Furthermore, differences have been noted
in proteasome subunit activity in different tissue types14 and
cell lines15,46 as well as in primary cells from different leukemia
patients.20 As a preliminary survey, we examined ChL, CaL, and
TL activities from several purified sources (yeast, rabbit, and
human constitutive and immunoproteasomes; Figure 5). All of
the proteasome sources hydrolyze ChL1−488 most rapidly,
followed by TL1−550 and then CaL1−633 (data not shown).
However, this ordered ranking of activities does not necessarily
provide a quantitative assessment of the inherent catalytic
prominence of the respective active sites. Indeed, although ChL
Figure 4. Proteasome signature of HeLa cells. (a) Activity of proteasome from HeLa cells with ChL1−488, TL1−550, and CaL1−633 sensors. The
26S fraction is the resuspended pellet after ultracentrifugation containing the proteasome and the ID 26S fraction is the immunodepleted 26S
fraction. (b) Reproducibility of the ratios of proteasome activity from HeLa cell ultracentrifugation fractions.
Figure 5. Proteasome catalytic signatures, ratios of ChL/TL and ChL/
CaL, vary from different species and sources.
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activity is commonly thought to be preeminent in terms of
protein degradation,4 the importance of the TL and CaL sites
has recently garnered significant attention.21,23,47 The protea-
some sensor set developed in this study provides a comparative
assessment of differences in these activities, thereby potentially
offering insight into enzymatic variations among species as well
as between normal and diseased cell types. In the latter case,
this may ultimately offer possible therapeutic opportunities with
respect to proteasomal targeting. The catalytic activities for the
various sources reveal significant differences (Figure 5). In
particular, the TL activity is more pronounced (versus ChL and
CaL) in yeast proteasome than the corresponding TL activity
from mammalian sources (Figure 5). The human erythrocyte
constitutive proteasome (β1, β2, and β5) exhibits TL/ChL and
CaL/ChL ratios that are 2 and 10 times lower, respectively,
than the ratios from the immunoproteasome (β1i, β2i, and β5i)
purified from human spleen.
Does the Proteasome Catalytic Signature Vary by
Disease State? The FDA approval of bortezomib in 2003 and
carfilzomib in 2012 to treat multiple myeloma and, in the case
of bortezomib, mantle cell lymphoma (a subtype of B-cell
lymphoma) illustrates the efficacy of anticancer agents that
inhibit the ChL activity of the proteasome.48 Bortezomib and
other proteasome inhibitors are also currently being tested in
combination therapy for numerous B-cell lymphomas.49
Consequently, we opted to test the proteasome sensors in
several cancerous B-cell lines as well as from normal B-cells
from healthy donors. Unlike HeLa cell lysates, where all three
proteolytic activities are easily distinguished, ChL activity is the
only measurable activity in proteasomes from normal B-cells
(Supporting Information Figure 13). Furthermore, ChL
proteasomal activity dwarfs the observed TL and CaL activities
in proteasomes isolated from the cancerous B-cell lines HBL-1
and OCl-Ly3 (Supporting Information Figure 13). However,
relative ChL activity, when compared to the total amount of
proteasome, as assessed by the amount of α7 proteasome
subunit present, is 3−5-fold higher in the cancerous B-cell lines
than that in normal B-cells (Figure 6a). We also found that
normal B-cells predominantly express the immunoproteasome
catalytic subunits (β1i, β2i, and β5i), whereas, the cancerous B-
cell lines possess both the constitutive (β1, β2, and β5) and the
immunoproteasome catalytic subunits (Figure 6b).
Distinctive proteasome activity has been reported by others,
suggesting that ChL activity is higher in cancerous cells
lines;18,19 however, Driessen et al. failed to observe any
correlation between ChL activity and cancer in leukemia
patients.20 In addition, other studies suggest that bortezomib
resistance occurs in cells with high ChL and CaL activities.20,26
While all of these studies have utilized APBs and/or short-
wavelength peptide sensors to show important differences in
proteasome activity and responses to inhibitors, we believe that
the sensor set developed here provides a needed approach that
allows for real-time analysis of all three proteolytic activities.
The use of APBs has proven to be a powerful tool for isolating
and identifying proteases that are in an active state both in cell
lysates and in cell culture.50 Fluorescently tagged APBs have
been critical in understanding protease activation at the
subcellular level.50 Furthermore, ABPs have successfully been
used in drug development for identifying inhibitors.50 APBs for
the proteasome have been utilized to distinguish activation of
the constitutive proteasome (β1, β2, and β5) versus the
immunoproteasome (β1i, β2i, and β5i) as well as establishing
which subunits are inhibited in cells by anticancer agents such
as bortezomib.32 However, there are limitations of APBs that
can be addressed with peptide sensors. Proteasome activity is
known to be effected by subunit composition as well as
numerous regulatory proteins. Therefore, APBs that monitor
the amount of catalytically competent enzyme at a single time
point50 do not furnish an understanding of how enzymatic
activity is altered by regulatory proteins or post-translational
modifications. The peptide sensors described here are not
specific for the proteasome over other proteases but do
provided a direct measure of the levels of enzymatic activity
when working with lysates or purified samples. Unlike APBs,
fluorescent peptide sensors amplify the signal and can therefore
be used with smaller concentrations of enzymes for real-time
monitoring of enzymatic activity. Although short-wavelength
peptides are available for monitoring the individual activities of
the proteasome, there are no peptide sensors that permit the
monitoring of all activities in a single assay, thereby affording a
true understanding of the proteasome catalytic efficiency.
Although the sensors described in this study are sufficient for
use with isolated proteasomes, live cell studies will require the
development of proteasome-selective analogues. In addition,
live cell imaging of enzymatic activity necessitates a well-defined
start point. This may be feasible using light-activated derivatives
of these sensors by employing a strategy analogous to a
previously described approach.51
The proteasome is responsible for the proteolytic breakdown
of polyubiquitinated proteins in all cells. It plays important
roles in protein turnover, cell division, autophagy, and antigen
presentation. In addition, altered proteasome function has been
linked to aging, cardiac hypertrophy, neurodegeneration, and
cancer. Therefore, methods to monitor the three proteolytic
activities (the “catalytic signature”) of the proteasome are
necessary for understanding such processes. We have described
a proteasome sensor triad for the simultaneous fluorescent
monitoring all three proteasomal protease activities. These
sensors were used to demonstrate that the catalytic signature of
the proteasome is unique to each cell line. Furthermore, in B-
Figure 6. Proteasome catalytic signature and subunit composition from B-cells. (a) Relative proteasome ChL1−488 activity from B-cells. (b)
Western blots showing the different subunit composition of the proteasome in the different B-cell lines. B4 and B5 are normal B-cells from health
donors, HBL-1 and OCI-Ly3 are cancerous B-cell lines, and HBL-1 ID and OCI-Ly3 ID are the corresponding immunodepleted samples.
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cells, only ChL activity is detectable, and cultured cancerous B-
cells have higher ChL activity than in normal B-cells. The
simultaneous monitoring of the multiple activities of the
proteasome offers the ability to assess the proteasome catalytic
signature, which could prove to be a barometer of various
cellular and diseased states.
■ METHODS
Materials. Rabbit proteasome fraction II was purchased from
Sigma. Human erythrocyte 26S proteasome and human spleen
immunoproteasome 20S were purchased from Enzo Life Sciences.
Purified rabbit 20S proteasome was purchased from Calbiochem. All
Proteasome inhibitors were purchased from Enzo Life Sciences. HeLa
cells were purchased from the tissue culture facility at the University of
North Carolina. Normal B-cells were purchased from AllCells. OCI-
Ly3 and HBL-1 cells were provided by Dr. Ben Major in the
Department of Cell Biology and Physiology at the University of North
Carolina. The BCA kit (Thermo Scientific) was used to quantify the
protein content of all lysates. All other chemicals were from Fisher or
Sigma unless otherwise noted.
Assessment of Proteasome Activity. All data is reported as the
mean ± standard deviation of triplicate assays, where FU is fluorescent
units.
Rates and Fold Changes. The activities of all proteasomes were
determined in assay buffer (50 mM Tris, pH 7.5, 40 mM KCl, 4 mM
MgCl2, 1 mM ATP, 1 mM EDTA) and 0.05% bovine serum albumin
(BSA)4 with 0−5 μM of each proteasome sensor. The reactions were
initiated with 1−40 μg of proteasome, and the reaction progress was
monitored for 2 h at RT unless otherwise noted. For determination of
the fluorescent fold change, each reaction was spiked with 10 μg of
rabbit fraction II proteasome and incubated at RT overnight. Control
assays without proteasome were run to ensure that the fluorescent
change was due to proteasome activity and not hydrolysis.
Fluorescence was monitored on Molecular Devices Spectra Max
Gemini EM plate reader with excitation at 490, 550, and 625 nm, with
emission at 515, 575, and 655 nm, respectively. SigmaPlot 12
(775206611) was used for the analysis of all data. The rate of each
assay was determined using a linear fit to the first 10% of substrate
consumption. Fold changes were determined by dividing the final
fluorescence by the initial fluorescence. Conversion of fluorescence
change to micromoles of product formed was determined by assuming
that the reaction was 95% complete after determining the fold change.
A linear fit was then applied to the fluorescence at 0, 1, 2.5, and 5 μM,
allowing the conversion from fluorescent units to micromoles.
Inhibition. Unless otherwise noted, 5.5 μg of rabbit proteasome
fraction II was preincubated with inhibitor in assay buffer at 37 °C for
30 min. The reaction was initiated with 0−5 μM proteasome sensor.
Activity was measured as described above. For N-α-tosyl-L-lysinyl-
chloromethylketone (TLCK) inhibition, 5.5 μg of rabbit proteasome
fraction II or 7.8 μg of control yeast deficient lysate was incubated with
TLCK in buffer, pH 5.5, at 37 °C for 30 min. The incubation was
diluted 1:10 in assay buffer, and the reaction was initiated with 0−5
μM proteasome sensors. All data was fit to the standard IC50 equation
and plotted using SigmaPlot.
Yeast Proteasome Activity-Deficient Lysates. Harvested cells
expressing proteasome-deficient mutants were purified as described
recently.41,52 Cells were drop-frozen in liquid nitrogen, and lysis was
carried out by cryomilling. The corresponding powders were stored at
−80 °C. Lysates were resuspended in assay buffer on ice for 10 min
and centrifuged at 10 000g at 4 °C for 30 min. The lysate protein
concentration was determined using the BCA assay. Proteasome assays
were run as described above for the rates with 34 μg of each lysate.
The rate of each assay was determined using a linear fit to the first 10%
of substrate consumption.
Cell Culture. HeLa cells were passaged by treatment with 0.5%
trypsin + 0.53 mM EDTA before reaching confluence and maintained
in DMEM containing 10% fetal bovine serum (FBS), nonessential
amino acids, and penicillin−streptomycin at 37 °C in a 5% CO2
incubator. HBL-1 and OCI-Ly3 cells were maintained between 3 × 105
and 1 × 106 in RPMI 1640 media containing 15% FBS supplemented
with penicillin−streptomycin at 37 °C in a 5% CO2 incubator.
Proteasome-Enriched Cell Extracts. One 90% confluent 75 cm2
flask of HeLa cells or 25 mL of HBL-1 or OCI-Ly3 cells at 6 × 105
were used to isolate a cell fraction to monitor proteasome activity
while removing other protease activity.4 Isolated cells were
resuspended in ice-cold PBS and centrifuged at 1000g for 5 min at
4 °C for 3 cycles. Cells were then resuspended in 4 volumes
homogenization buffer (50 mM Tris, 250 mM sucrose, 5 mM MgCl2,
1 mM ATP, 1 mM DTT, 0.5 mM EDTA, pH 7.5) with 0.025%
digitonin and incubated on ice for 10 min, followed by centrifugation
at 17 000g for 10 min at 4 °C. The supernatant was then
ultracentrifuged at 180 000g for 4 h at 4 °C. The supernatant was
removed, and the pellet was resuspended in homogenization buffer.
Protein concentration was determined using the BCA kit from
Thermo Scientific.
Immunodepletion and Western Blots. Proteasome 20S core
subunits, 20S β1, 20S β2, 20S β5, 20S α7, and 11S α, and 19S ADRM1
antibodies were purchased from Enzo Life Sciences. Proteasome 20S
β1i and 20S β5i antibodies were purchased from Thermo Fisher
Scientific. Proteasome 20S β2i antibody was purchased from
NovusBio. All secondary antibodies were purchased from GE
Healthcare.
Immunodepletion of proteasome from cell lysates was accomplished
by incubating lysates (1 mg) with 20 μL of proteasome 20S core
subunits primary antibody at 4 °C overnight. The mixture was added
to 200 μL of Protein A-sepharose 4B beads from Invitrogen
(prewashed with homogenization buffer), incubated for 1 h at 4 °C,
and loaded in a spin column, and the supernatant was collected as the
immunodepleted fraction. Immunodepletion was confirmed by
western blot. Quantification of the immunodepletion was performed
using ImageJ software.
Western blots of all samples, 50 μg per well, were performed on 4−
20% SDS Tris-HCl gels (BioRad) and transferred to nitrocellulose
membranes. Membranes were blocked with 5% BSA in PBS + 0.1%
Tween-20 for 2 h before incubation with 1:500 of the primary
antibody in the blocking solution at 4 °C overnight. Membranes were
washed with PBS + 0.1% Tween-20, incubated with 1:5000 secondary
HRP conjugated antibody for 2 h, and washed with PBS. Visualization
was performed according to Pierce’s recommended protocols for their
ECL Pico kit. Images were acquired using an Alpha Innotech
Fluorchem FC2 using the chemiluminescent settings.
Proteasome Assays with Cell Lysates. The activity of all cell
lysates and immunodepleted samples was determined in assay buffer
with 0.05% BSA and 0.5 μM ChL1−488, 1 μM TL1−550, and 1 μM
CaL1−633. The reactions were initiated with 10 μg of cell lysate, and
the reaction progress was monitored for 2 h at RT. Control assays
without cell lysate were run to ensure that the fluorescent change was
due to proteasome activity and not hydrolysis. Fluorescence was
monitored on Molecular Devices Spectra Max Gemini EM plate reader
with excitation at 490, 550, and 625 nm and emission at 515, 575, and
655 nm, respectively. SigmaPlot was used for the analysis of all data.
The rate of each reaction was determined using a linear fit to the first
10% of substrate consumption.
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